- Price
- $1,148.20
- Day
- -0.98%
- Mkt Cap
- $1.08T
- 52W Range
- $712.05 – $1,292.65
- Volume
- 2.15M
- Beta
- 0.50
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Here's Why Billionaires Stanley Druckenmiller and Ken Griffin Are Loading Up on Eli Lilly Stock
Griffin's Citadel Advisors and Druckenmiller's Duquesne Family Office bought Lilly stock in Q2. The billionaires likely capitalized on an opportunity with Lilly's shares tumbling early in the quarter.
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.
Eli Lilly hasn't split its stock in nearly 30 years, but as shares trade above $1,000, the pharmaceutical company could be considering one. Considering other high-profile stock splits in recent years, count on company-specific catalysts, not the split itself, to drive further gains.
Great News for Eli Lilly Stock Investors
Eli Lilly's tirzepatide is showing potential across autoimmune diseases. The medicine could earn additional indications and attract broader insurance coverage over time.
Aspen sees Mounjaro Africa sales above $124 million in 2027
Aspen Pharmacare expects African sales of Eli Lilly's blockbuster weight-loss and diabetes drug Mounjaro to exceed 2 billion rand ($124 million) in its current financial year, buoyed by surging demand in South Africa and planned launches in Nigeria and Kenya.